Hologic Inc

Hologic — Debt Investor Presentation (February 2014)

20 slides from Hologic's debt investor presentation, Feb 13, 2014

  1. Slide 1: Presentation to Lenders

    Exhibit 99.1 Presentation to Lenders February 13, 2014

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking information that involves risks and uncertainties, including statements about the Company’s plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information included herein bas

  3. Slide 3: Transaction Overview

    Transaction Overview Hologic, Inc. ("Hologic" or "the Company") (NASDAQ: HOLX) is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products, with an emphasis on serving the healthcare needs of women Hologic has continued to demonstr

  4. Slide 4: Pro Forma Capitalization

    Pro Forma Capitalization Amounts as of December 28, 2013 ($ in millions) Current Pro Forma Amount Amount Leverage Coupon Floor Maturity Put Date Cash $ 449 $ 449 Revolver ($300mm) - - - L + 200 - Aug-17 Term Loan A 932 932 1.0 x L + 200 - Aug-17 Extant Term Loan B 1,171 - - L + 275 1.00% Aug-19 New

  5. Slide 5: Total Revenues by Business Segment

    Total Revenues by Business Segment Consolidated Q1’14 Revenues of $612.4M (unaudited) Total Diagnostics $285.8M 47% 16% Service Breast Health $226.5M 37% 20% Capital Equipment 64% Consumables GYN Surgical $78.8M 13% Skeletal Health $21.3M 3% Consumables/Service ~80% Capital Equipment ~20% 5

  6. Slide 6: Two Exciting Product Cycles are Just Beginning

    Two Exciting Product Cycles are Just Beginning • Early stage of a promising replacement cycle with technology superior to 2D digital • Additional peer-reviewed publications further support adoption Dimensions 3D Breast Tomosynthesis • Ability to offer class-leading automation to low- and medium- vol

  7. Slide 7: Diagnostics – Leadership in Cytology and Molecular Diagnostics

    Diagnostics –Leadership in Cytology and Molecular Diagnostics • Premier automated solutions • Proprietary chemistries: TMA (Transcription-mediated amplification) and Invader • Extending leadership from cytology into molecular via Gen-Probe acquisition • Validated by #1 or #2 U.S. market share in key

  8. Slide 8: Comprehensive Cervical Cancer Screening Solution

    Comprehensive Cervical Cancer Screening Solution • The only FDA approved complete cervical cancer screening solution to include liquid-based cytology + HPV (high-risk and genotyping) • All from our ThinPrep vial, the gold standard in cervical cytology • Thoughtfully designed HPV products designed to

  9. Slide 9: Breast Health – Mammography

    Breast Health –Mammography Leader in Breast Cancer Screening & Diagnosis – Market leadership: ~65% of current U.S. installed base, ~40% OUS – Approximate $4 billion addressable U.S. market – Strong competitive advantages of 3D Dimensions • Clinical superiority to 2D • First-to-market with no U.S. To

  10. Slide 10: 3D Dimensions Tomosynthesis

    3D Dimensions Tomosynthesis Superior Next-Generation Digital Mammography Improved Tissue Visualization and Detection Superiority over 2D Digital Mammography Lower Recall Rates Tomosynthesis…uptake ahead of expectations – U.S. installed base of ~11,000 digital systems potential – for conversion to To

  11. Slide 11: Tomosynthesis Clinical Efficacy

    Tomosynthesis Clinical Efficacy Oslo Tomosynthesis Screening Trial Compared to 2D, U.S. sites report a significant reported breast cancer screening reduction in recalls with 2-3 with Hologic Tomosynthesis significantly Hologic Tomosynthesis improves cancer detection(1) 40% 27% in invasive overall in

  12. Slide 12: MyoSure a Growth Driver in GYN Surgical

    MyoSure a Growth Driver in GYN Surgical MyoSure Hysteroscopic Tissue Removal System • Minimally-invasive technology to remove fibroids and polyps • Dynamic technology in early stages of adoption • Potential $300-400 million annual opportunity in the U.S. • Product line extensions offer flexibility t

  13. Slide 13: Q1 FY 2014 Overview

    Q1 FY 2014 Overview Quarter Ended December 28, 2013 (unaudited) Key Performance Metrics Q1 FY 2014 Revenues of $612.4 million Revenues* • Revenues down $18.9 million, or 3.0%, vs. Q1’13 (1) (and down $32.2 million or 5.0% vs. Q1’13 non-GAAP revenues) GAAP net loss of $5.4 million and Net Income* non

  14. Slide 14: Four Business Segments

    Four Business Segments Breakdown of Q1 FY 2014 Revenues of $612.4M (unaudited) 37% 64% Breast Health Disposables 13% GYN Surgical 16% 47% Service 20% Diagnostic Capital Equipment U.S. Revenues ~ 75% Disposables/Service ~ 80% International Revenues ~ 25% Capital Equipment ~ 20% 14

  15. Slide 15: Amendment Overview

    Amendment Overview Hologic is seeking to reprice its Term Loan B Term Loan B offered at par 101 soft-call refreshed for 6 months 15

  16. Slide 16: cai). Bog

    cai). 79 Bog FS HOLOGIC ae

  17. Slide 17: Reconciliation of GAAP to Non-GAAP (unaudited)

    Reconciliation of GAAP to Non-GAAP (unaudited) In thousands, except earnings per share Three Months Ended December 28, 2013 December 29, 2012 REVENUES GAAP revenues $612,448 $631,362 Adjustments primarily related to blood screening collaboration - 13,275 Non-GAAP revenues $612,448 $644,637 EARNINGS

  18. Slide 18: Reconciliation of GAAP to Non-GAAP (unaudited)

    Reconciliation of GAAP to Non-GAAP (unaudited) In thousands Three Months Ended December 28, 2013 December 29, 2012 OPERATING EXPENSES GAAP operating expenses $244,311 $218,444 Adjustments: Amortization of intangible assets (26,216) (28,526) Contingent consideration - (39,526) Acquisition and integra

  19. Slide 19: Operating Cash Flow (unaudited)

    Operating Cash Flow (unaudited) In thousands Three Months Ended December 28, 2013 ADJUSTED NET CASH PROVIDED BY OPERATING ACTIVITIES Net cash provided by operating activities (GAAP) $149,266 Contingent consideration paid for acquisitions (GAAP, within operating activities) 31,202 1 Adjusted net cash

  20. Slide 20: Use of Non-GAAP Financial Measures

    Use of Non-GAAP Financial Measures Hologic has presented a number of non-GAAP financial measures that it uses to monitor its business and present to investors as set forth and reconciled in the preceding pages. Hologic defines its non-GAAP revenues to primarily include contingent revenue earned unde

Hologic — Debt Investor Presentation (February 2014) on 6ix